Kadimastem: Hadassah approvals IRB for conducting a clinical trial in ALS Patients

Israeli biotechnology company Kadimastem has received approval from the IRB (Helsinki Committee) of the Hadassah Ein Kerem Hospital for the phase I/IIa clinical trial in ALS patients using the cell therapy product developed by the Company. The commencement of the clinical trial is subject…